Psychiatric Times

The April issue of Psychiatric Times is now live! This month, we take closer look at reality TV. Is it reducing stigma or raising risks? Download the issue now and follow along as articles are shared throughout the month. cdn.sanity.io/files/0vv8moc6…

ONLINE NOW! In this interview w/ @PsychTimes, @EmmaGuttman @MSHSDerm & @JMurrough @IcahnDAC discuss their research collaboration linking inflammatory pathways in atopic dermatitis to the pathophysiology of #MajorDepressiveDisorder. Watch Interview Here 👉 psychiatrictimes.com/view/depressio…

Deep intracranial frequency stimulation 77.5 Hz high-gamma approach was associated with statistically significant reductions in self-injury behaviors and depressive symptoms in female adolescents with nonsuicidal self-injury, according to a new study. psychiatrictimes.com/view/deep-intr…

Stroke meets CMS chronic-condition criteria, yet therapy reimbursement commonly ends at 2–3 months, despite evidence that function and skills can improve at any time poststroke. So why aren’t we practicing that type of medicine in chronic strokes? psychiatrictimes.com/view/why-arent…

The first participants have now been enrolled in a US Department of War-funded phase 2a clinical trial evaluating sublingual dexmedetomidine (BXCL501) for the treatment of acute stress reactions. @BioXcel_Tx psychiatrictimes.com/view/first-par…

Ultimately, psychiatry is two people in a room trying to better understand the world, and themselves. That requires the honest, caring exchange of ideas. If you come in with relationship problems, my job isn’t to push you to stay or leave. It’s to help you understand yourself more clearly through it. Discussion and debate are at the core of what we do, they’re the very process by which we help people understand their lives. Yet modern medicine often does them poorly. So a few colleagues and I created a psychiatry debate competition. The goal isn’t to declare winners. It’s to model the kind of rigorous, respectful dialogue our field should be built on. The first finals will be held at the APA. I also wrote an article with some of this year’s participants on the motion: “Should Accrediting Bodies Require AI for Suicide Risk Stratification in Emergency Settings?” @PsychTimes featured it on their homepage. I’d be grateful if you read it, or better yet, join us at the APA to watch psychiatry residents debate important topics with intelligence and respect.

Early MRS data show AL001 delivers lithium effects across the brain while sparing glutamate, hinting at better tolerability than lithium carbonate. @AlzamendNeuro psychiatrictimes.com/view/encouragi…

🥦 It's time to take a closer look at mood and food. Let's explore new developments coming out of the field of nutritional psychiatry. psychiatrictimes.com/view/what-is-t…

Psychiatrists and mental health clinicians: We want to know your thoughts on the addictive nature of social media📱⬇️ Is social media addictive?

Psychedelics for the treatment of depression: strong interventions that must be handled with the utmost care. youtube.com/shorts/PJ0mGZw…

Oral brexanolone LPCN 1154 for the treatment of postpartum depression failed to meet the primary endpoint in a phase 3 placebo-controlled trial. psychiatrictimes.com/view/lpcn-1154…

Our April theme: Schizophrenia. If you are interested in being featured in a future Special Report/print issue, submit to our content series! psychiatrictimes.com/view/presentin…

Alkermes has announced the initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared with placebo in adults with narcolepsy type 1 and narcolepsy type 2. @Alkermes psychiatrictimes.com/view/phase-3-b…

A panel of experts presented new consensus recommendations focused on the screening, diagnosis, and treatment of tardive dyskinesia among older adults in long-term care settings. psychiatrictimes.com/view/first-exp…

As the month comes to a close, let's take a look at all the recent psychopharmacology updates: psychiatrictimes.com/view/march-202…

GLP-1 medications may have problematic interactions with eating disorders. Learn more in our latest YouTube short: youtube.com/shorts/jnM0gd1…

Interim results from a phase 2 trial of tazbentetol for treatment of schizophrenia showed trends of improving positive and negative symptoms in patients via synaptic regeneration. @Spinogenix_Inc psychiatrictimes.com/view/tazbentet…

The ASAM has announced new youth substance use disorder criteria, promoting early intervention, family-focused care, integrated mental health, and updated levels of treatment. psychiatrictimes.com/view/asam-anno…

New in @PsychTimes. Culture as Wind: Adapting Recovery&Shared Decision-Making Across Cultures Same recovery/SDM approach can be used well in one context, but less smoothly in another. Culture shapes what good care looks like. Quick “wind-check” can help psychiatrictimes.com/view/culture-a…

Proactive ICU psychiatry reduces delirium, length of stay, and readmissions while advancing equity and value-based critical care. psychiatrictimes.com/view/racing-to…